ClinicalTrials.gg
CompletedNCT02189304Updated Jun 13, 2018

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

A Phase 1 interventional study of PT010 and PT009 in COPD, sponsored by Pearl Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2014, 12 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
26th of 43
59 · median 99
Started
2014
with 3 others
Phase 1
6 of 43
none open now
Registered
19th of 43
by date
Lead sponsor
7 of 43
Pearl Therapeutics, Inc.

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 26th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 1, and was the 19th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a single-center, Phase I, healthy adult subject study with a randomized, double blind, three period, three-treatment, cross-over design.

03

Conditions studied

  • COPD

Keywords

  • Healthy volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Form (ICF) prior to any study related procedures
  • Male and female subjects 18 to 55 years, inclusive
  • Good general health
  • Medically acceptable for women of and males with female partners of childbearing potential
  • Clinical labs within normal ranges or determined to be not by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, nursing female subjects, or subjects trying to conceive
  • neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study
  • History of abnormalities
  • Cancer not in complete remission for at least 5 years
  • Clinically significant, symptomatic prostatic hypertrophy
  • Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening
  • Clinically significant bladder neck obstruction or urinary retention
  • Inadequately treated glaucoma
  • History of an allergic reaction or to any drug or to any component of the formulations used in this study
  • Subjects with pre-existing anemia and/or iron deficiency
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    PT010

    PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations

    Drug: PT009 · Drug: Symbicort Turbohaler

  • Experimental
    PT009

    PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations

    Drug: PT010 · Drug: Symbicort Turbohaler

  • Active comparator
    Symbicort Turbohaler

    Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations

    Drug: PT010 · Drug: PT009

Interventions

  • DrugPT010

    PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations

    Also known as: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol

  • DrugPT009

    PT009 administered as 2 inhalations

    Also known as: PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations

  • DrugSymbicort Turbohaler

    Drug pages: Budesonide · Formoterol

    Symbicort Turbohaler taken as 2 inhalations

    Also known as: Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder

06

What researchers measure

Primary outcomes

  1. Overall Safety of PT010, PT009 and Symbicort Turbohaler

    The safety of PT010 and PT009 and Symbicort Turbohaler will be assessed based on physical examination, adverse events, vital signs, clinical laboratory values, and electrocardiogram

    Time frame: 12 hours post dose

Secondary outcomes

  1. ◦Maximum plasma concentration (Cmax) of PT010, PT009 and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  2. ◦Area under the curve from 0 to 12 hours (AUC0 12) of PT010, PT009 and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  3. ◦Area under the curve from 0 to the time of the last measureable plasma concentration (AUC0 t) of PT010, PT009 and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  4. ◦Area under the curve from 0 extrapolated to infinity (AUC0-∞) of PT010, PT009, and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  5. ◦Time to maximum plasma concentration (tmax) of PT010, PT009, and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  6. ◦Apparent terminal elimination half life (t½) of PT010, PT009, and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  7. ◦Apparent total body clearance (CL/F) of PT010, PT009, and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  8. ◦Apparent volume of distribution (Vd/F) of PT010, PT009, and Symbicort Turbohaler

    Time frame: 12 Hour post dose

  9. ◦Termination elimination rate constant (λz) of PT010, PT009, and Symbicort Turbohaler

    Time frame: 12 Hour post dose

07

Study locations

1 site
  • SNBL Clinical Pharmacology Center
    Baltimore, Maryland 21201, United States
08

References and documents

Publications

  • Huang Y, Assam PN, Feng C, Su R, Dorinsky P, Gillen M. Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Pulm Pharmacol Ther. 2020 Oct;64:101976. doi: 10.1016/j.pupt.2020.101976. Epub 2020 Nov 2. PubMed 33152467 ↗
  • Maes A, DePetrillo P, Siddiqui S, Reisner C, Dorinsky P. Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. Clin Pharmacol Drug Dev. 2019 Feb;8(2):223-233. doi: 10.1002/cpdd.585. Epub 2018 Jun 14. PubMed 29901860 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Sep 2014, 3 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 3 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2014
First posted
Jul 14, 2014
StartActual
Jun 1, 2014
Primary completionActual
Sep 1, 2014
CompletionActual
Sep 1, 2014
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02189304
Responsible party
Sponsor
First posted
Jul 14, 2014
Start date
Jun 1, 2014
Primary completion
Sep 1, 2014
Completion
Sep 1, 2014
Last update
Jun 13, 2018

Study contacts

Chadwick Orevillo
study chair · Pearl Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PT010 · Budesonide · Formoterol

Start the discussion